Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03

AUTHORS

Anne Gardin, Mike Ufer, Eric Legangneux, Gianluca Rossato, Yi Jin, Zhenzhong Su, Parasar Pal, Wenkui Li, Kasra Shakeri-Nejad

ABSTRACT

OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Study B). METHODS: Study A was an open-label, single-dose study comprising periods 1 (14 days; day 1: siponimod 4 mg) and 2 (20 days; day 1: fluconazole 200 mg twice daily; days 2-19: fluconazole 200 mg once daily; day 3: siponimod 4 mg) in healthy subjects (n = 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25 mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25 mg once daily; day 3: 0.5 mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n = 24). Pharmacokinetic parameters were calculated using noncompartmental methods. RESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160 h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0 ng/mL) and elimination half-life (T½; from 40.6 to 61.6 h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T½ was prolonged in the CYP2C9*2/*3 (51 h) and CYP2C9*3/*3 (126 h) genotypes versus the CYP2C9*1/*1 (28 h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies. CONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans. More... »

PAGES

349-361

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3

DOI

http://dx.doi.org/10.1007/s40262-018-0700-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106022094

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30088221


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardin", 
        "givenName": "Anne", 
        "id": "sg:person.0746041340.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ufer", 
        "givenName": "Mike", 
        "id": "sg:person.0614623553.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614623553.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legangneux", 
        "givenName": "Eric", 
        "id": "sg:person.01152111734.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossato", 
        "givenName": "Gianluca", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jin", 
        "givenName": "Yi", 
        "id": "sg:person.0757541121.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757541121.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Beijing Novartis Pharmaceuticals Corporation, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Su", 
        "givenName": "Zhenzhong", 
        "id": "sg:person.015620100105.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015620100105.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Parasar", 
        "id": "sg:person.0615427741.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Institutes for Biomedical Research, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Wenkui", 
        "id": "sg:person.01314355711.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314355711.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shakeri-Nejad", 
        "givenName": "Kasra", 
        "id": "sg:person.01367544315.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaneurol.2016.1451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011275377"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaneurol.2016.1451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011275377"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.108.020396", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013227922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2008.302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015890832", 
          "https://doi.org/10.1038/clpt.2008.302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/pgs.10.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020935714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/nyas.12821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023965742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023978690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2004.08.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033907987", 
          "https://doi.org/10.1016/j.clpt.2004.08.009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2133/dmpk.dmpk-12-rv-085", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043672512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2015.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047057921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2015.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047057921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/blr.2006.25.447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059238419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00008571-200309000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060290069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/fpc.0b013e3283349e84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060340789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082883663", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03", 
    "datePublishedReg": "2019-03-01", 
    "description": "OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole\u00a0(Study A), and (2) with three different CYP2C9 genotype variants\u00a0(Study B).\nMETHODS: Study A was an open-label, single-dose study comprising periods 1 (14\u00a0days; day 1: siponimod 4\u00a0mg) and 2 (20\u00a0days; day 1: fluconazole 200\u00a0mg twice daily; days 2-19: fluconazole 200\u00a0mg once daily; day 3: siponimod 4\u00a0mg) in healthy subjects (n\u2009= 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25\u00a0mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25\u00a0mg once daily; day 3: 0.5\u00a0mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n\u2009= 24). Pharmacokinetic parameters were calculated using noncompartmental methods.\nRESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160\u00a0h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0\u00a0ng/mL) and elimination half-life (T\u00bd; from 40.6 to 61.6\u00a0h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T\u00bd was prolonged in the CYP2C9*2/*3 (51\u00a0h) and CYP2C9*3/*3 (126\u00a0h) genotypes versus the CYP2C9*1/*1 (28\u00a0h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies.\nCONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40262-018-0700-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "name": "Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects", 
    "pagination": "349-361", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c12c77da7653d5747ef1139b8707361a28985ba0fef3adc5ff96e36faef3a19b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30088221"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40262-018-0700-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106022094"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40262-018-0700-3", 
      "https://app.dimensions.ai/details/publication/pub.1106022094"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11707_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40262-018-0700-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40262-018-0700-3'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      21 PREDICATES      50 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40262-018-0700-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4e2dc2c05f3146c0979e3df91dd82be6
4 schema:citation sg:pub.10.1007/s00228-017-2404-2
5 sg:pub.10.1016/j.clpt.2004.08.009
6 sg:pub.10.1038/clpt.2008.302
7 https://app.dimensions.ai/details/publication/pub.1082883663
8 https://doi.org/10.1001/jamaneurol.2016.1451
9 https://doi.org/10.1002/jcph.561
10 https://doi.org/10.1016/j.clinthera.2015.09.006
11 https://doi.org/10.1016/s0140-6736(18)30475-6
12 https://doi.org/10.1016/s1474-4422(13)70102-9
13 https://doi.org/10.1089/blr.2006.25.447
14 https://doi.org/10.1097/00008571-200309000-00005
15 https://doi.org/10.1097/fpc.0b013e3283349e84
16 https://doi.org/10.1111/j.1365-2125.2012.04400.x
17 https://doi.org/10.1111/j.1476-5381.2012.02061.x
18 https://doi.org/10.1111/nyas.12821
19 https://doi.org/10.1124/dmd.108.020396
20 https://doi.org/10.1124/dmd.117.079574
21 https://doi.org/10.2133/dmpk.dmpk-12-rv-085
22 https://doi.org/10.2217/pgs.10.49
23 https://doi.org/10.5414/cp202588
24 https://doi.org/10.5414/cp202608
25 schema:datePublished 2019-03
26 schema:datePublishedReg 2019-03-01
27 schema:description OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Study B). METHODS: Study A was an open-label, single-dose study comprising periods 1 (14 days; day 1: siponimod 4 mg) and 2 (20 days; day 1: fluconazole 200 mg twice daily; days 2-19: fluconazole 200 mg once daily; day 3: siponimod 4 mg) in healthy subjects (n = 14) with the wild-type CYP2C9 genotype (CYP2C9*1/*1). Study B was a multicentre, open-label study comprising parts 1 (day 1: siponimod 0.25 mg once daily in the CYP2C9*1/*1, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes) and 2 (days 1-2: 0.25 mg once daily; day 3: 0.5 mg once daily in the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes only) in healthy subjects with polymorphic variants of CYP2C9 (n = 24). Pharmacokinetic parameters were calculated using noncompartmental methods. RESULTS: In Study A, coadministration with fluconazole produced an approximately twofold increase in mean area under the curve (AUC) versus siponimod alone (from 1110 to 2160 h*ng/mL), and an increase in maximum plasma concentration (Cmax; from 31.2 to 34.0 ng/mL) and elimination half-life (T½; from 40.6 to 61.6 h). In Study B, the AUCs of siponimod were approximately two to fourfold greater in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, with a minor increase in Cmax versus the CYP2C9*1/*1 genotype. The mean T½ was prolonged in the CYP2C9*2/*3 (51 h) and CYP2C9*3/*3 (126 h) genotypes versus the CYP2C9*1/*1 (28 h) genotype. Siponimod did not result in increased adverse events in healthy subjects in both studies. CONCLUSIONS: Changes in siponimod PK, when coadministered with fluconazole at steady-state and in subjects with different CYP2C9 genotypes, indicate that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. These results confirm the relevance of CYP2C9 activity on siponimod metabolism in humans.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N852df4ad70b84120aeadfc3769adc5fd
32 Ne065174f6e334940967debdadadd51f5
33 sg:journal.1085321
34 schema:name Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
35 schema:pagination 349-361
36 schema:productId N0bc06279e604408db73fecb4f28484a5
37 N232a26d5a9824e8b9c83480b53d60a0b
38 N2c63cdb9a7494177bb3ec692794f6562
39 Na6a65af7955b499f981af3730dbca425
40 Nf37ffaba352b4fc08ebe93297157a719
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106022094
42 https://doi.org/10.1007/s40262-018-0700-3
43 schema:sdDatePublished 2019-04-11T11:19
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N9a15867364a84844a1ff3333ae8a6d10
46 schema:url https://link.springer.com/10.1007%2Fs40262-018-0700-3
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N034eec091dc64545ac3f6aa6e81ce06a rdf:first sg:person.0614623553.04
51 rdf:rest N52ad910b88b5477f930c8ed521e91d73
52 N0bc06279e604408db73fecb4f28484a5 schema:name doi
53 schema:value 10.1007/s40262-018-0700-3
54 rdf:type schema:PropertyValue
55 N0c3eaa29f85e4766a9046e4190786f6e rdf:first sg:person.015620100105.09
56 rdf:rest Nbfc3215b0bde45d7a13bf8c814f0e987
57 N21c9be7f71d3429aa45838285f30521e schema:name Beijing Novartis Pharmaceuticals Corporation, Shanghai, China
58 rdf:type schema:Organization
59 N232a26d5a9824e8b9c83480b53d60a0b schema:name dimensions_id
60 schema:value pub.1106022094
61 rdf:type schema:PropertyValue
62 N2c63cdb9a7494177bb3ec692794f6562 schema:name readcube_id
63 schema:value c12c77da7653d5747ef1139b8707361a28985ba0fef3adc5ff96e36faef3a19b
64 rdf:type schema:PropertyValue
65 N4e2dc2c05f3146c0979e3df91dd82be6 rdf:first sg:person.0746041340.65
66 rdf:rest N034eec091dc64545ac3f6aa6e81ce06a
67 N52ad910b88b5477f930c8ed521e91d73 rdf:first sg:person.01152111734.09
68 rdf:rest Nf5fd5e2f233f459397ab64a54aa82fdc
69 N5c227d0b881345409935808e88b23916 rdf:first sg:person.01367544315.00
70 rdf:rest rdf:nil
71 N76e92b659687487da8d8cd94cb9b6d38 rdf:first sg:person.01314355711.34
72 rdf:rest N5c227d0b881345409935808e88b23916
73 N852df4ad70b84120aeadfc3769adc5fd schema:issueNumber 3
74 rdf:type schema:PublicationIssue
75 N860a5894c2584f42948dfc4bf3fb5475 rdf:first sg:person.0757541121.27
76 rdf:rest N0c3eaa29f85e4766a9046e4190786f6e
77 N9a15867364a84844a1ff3333ae8a6d10 schema:name Springer Nature - SN SciGraph project
78 rdf:type schema:Organization
79 Na6a65af7955b499f981af3730dbca425 schema:name pubmed_id
80 schema:value 30088221
81 rdf:type schema:PropertyValue
82 Naac80c3703b045f8b8f2d13a7da069e5 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
83 schema:familyName Rossato
84 schema:givenName Gianluca
85 rdf:type schema:Person
86 Nbfc3215b0bde45d7a13bf8c814f0e987 rdf:first sg:person.0615427741.32
87 rdf:rest N76e92b659687487da8d8cd94cb9b6d38
88 Ne065174f6e334940967debdadadd51f5 schema:volumeNumber 58
89 rdf:type schema:PublicationVolume
90 Nf37ffaba352b4fc08ebe93297157a719 schema:name nlm_unique_id
91 schema:value 7606849
92 rdf:type schema:PropertyValue
93 Nf5fd5e2f233f459397ab64a54aa82fdc rdf:first Naac80c3703b045f8b8f2d13a7da069e5
94 rdf:rest N860a5894c2584f42948dfc4bf3fb5475
95 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
96 schema:name Medical and Health Sciences
97 rdf:type schema:DefinedTerm
98 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
99 schema:name Clinical Sciences
100 rdf:type schema:DefinedTerm
101 sg:journal.1085321 schema:issn 0312-5963
102 1179-1926
103 schema:name Clinical Pharmacokinetics
104 rdf:type schema:Periodical
105 sg:person.01152111734.09 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
106 schema:familyName Legangneux
107 schema:givenName Eric
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09
109 rdf:type schema:Person
110 sg:person.01314355711.34 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
111 schema:familyName Li
112 schema:givenName Wenkui
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314355711.34
114 rdf:type schema:Person
115 sg:person.01367544315.00 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
116 schema:familyName Shakeri-Nejad
117 schema:givenName Kasra
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00
119 rdf:type schema:Person
120 sg:person.015620100105.09 schema:affiliation N21c9be7f71d3429aa45838285f30521e
121 schema:familyName Su
122 schema:givenName Zhenzhong
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015620100105.09
124 rdf:type schema:Person
125 sg:person.0614623553.04 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
126 schema:familyName Ufer
127 schema:givenName Mike
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614623553.04
129 rdf:type schema:Person
130 sg:person.0615427741.32 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
131 schema:familyName Pal
132 schema:givenName Parasar
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32
134 rdf:type schema:Person
135 sg:person.0746041340.65 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
136 schema:familyName Gardin
137 schema:givenName Anne
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65
139 rdf:type schema:Person
140 sg:person.0757541121.27 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
141 schema:familyName Jin
142 schema:givenName Yi
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757541121.27
144 rdf:type schema:Person
145 sg:pub.10.1007/s00228-017-2404-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922651
146 https://doi.org/10.1007/s00228-017-2404-2
147 rdf:type schema:CreativeWork
148 sg:pub.10.1016/j.clpt.2004.08.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033907987
149 https://doi.org/10.1016/j.clpt.2004.08.009
150 rdf:type schema:CreativeWork
151 sg:pub.10.1038/clpt.2008.302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015890832
152 https://doi.org/10.1038/clpt.2008.302
153 rdf:type schema:CreativeWork
154 https://app.dimensions.ai/details/publication/pub.1082883663 schema:CreativeWork
155 https://doi.org/10.1001/jamaneurol.2016.1451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011275377
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1002/jcph.561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023978690
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.clinthera.2015.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047057921
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/s0140-6736(18)30475-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101698897
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1016/s1474-4422(13)70102-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033439649
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1089/blr.2006.25.447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059238419
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1097/00008571-200309000-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060290069
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1097/fpc.0b013e3283349e84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060340789
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1111/j.1365-2125.2012.04400.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002553097
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1111/j.1476-5381.2012.02061.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043127544
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1111/nyas.12821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023965742
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1124/dmd.108.020396 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013227922
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1124/dmd.117.079574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103850020
180 rdf:type schema:CreativeWork
181 https://doi.org/10.2133/dmpk.dmpk-12-rv-085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043672512
182 rdf:type schema:CreativeWork
183 https://doi.org/10.2217/pgs.10.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020935714
184 rdf:type schema:CreativeWork
185 https://doi.org/10.5414/cp202588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834626
186 rdf:type schema:CreativeWork
187 https://doi.org/10.5414/cp202608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834636
188 rdf:type schema:CreativeWork
189 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
190 schema:name Novartis Institutes for Biomedical Research, East Hanover, NJ, USA
191 rdf:type schema:Organization
192 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
193 schema:name Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland
194 rdf:type schema:Organization
195 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
196 schema:name Novartis Healthcare Pvt. Ltd, Hyderabad, India
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...